+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Carcinoid Syndrome - Pipeline Insight, 2021

  • ID: 4845157
  • Drug Pipelines
  • March 2021
  • Region: Global
  • 60 pages
  • DelveInsight

FEATURED COMPANIES

  • Aquestive Therapeutics
  • Crinetics Pharmaceuticals
  • MORE
This “Carcinoid Syndrome - Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Carcinoid Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
  • Global coverage
Carcinoid Syndrome Understanding

Carcinoid Syndrome: Overview

Carcinoid Syndrome, refers to the array of symptoms that occur secondary to carcinoid tumors. Carcinoid syndrome is seen in individuals who have an underlying carcinoid tumor with spread to the liver. Carcinoid tumors are well-differentiated neuroendocrine tumors with secretory properties, releasing serotonin, along with a number of other active peptides. These tumors can arise anywhere along the primitive gut and are therefore found in the bronchial tree (airways) and along the gastrointestinal tract. Only about 10% of the people with a carcinoid tumor will develop carcinoid syndrome. Only about 10% of the people with a carcinoid tumor develop carcinoid syndrome.

"Carcinoid Syndrome - Pipeline Insight, 2021" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Carcinoid Syndrome pipeline landscape is provided which includes the disease overview and Carcinoid Syndrome treatment guidelines. The assessment part of the report embraces, in depth Carcinoid Syndrome commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Carcinoid Syndrome collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Carcinoid Syndrome R&D. The therapies under development are focused on novel approaches to treat/improve Carcinoid Syndrome.

Carcinoid Syndrome Emerging Drugs Chapters

This segment of the Carcinoid Syndrome report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Carcinoid Syndrome Emerging Drugs

Paltusotine: Crinetics Pharmaceuticals

Paltusotine, is a novel, oral, selective, nonpeptide, somatostatin receptor type 2 (SST2) agonists designed for the treatment of Carcinoid Syndrome, Neuroendocrine Tumors and Acromegaly. Somatostatin is a neuropeptide hormone that broadly inhibits the secretion of other hormones, including growth hormone, or GH, from the pituitary gland. It is designed as a once daily option for patients with acromegaly and neuroendocrine tumors that are currently treated by injected therapies. Crinetics plans to advance paltusotine into a Phase II trial for the treatment of carcinoid syndrome associated with NETs in 2021.

Carcinoid Syndrome: Therapeutic Assessment

This segment of the report provides insights about the different Carcinoid Syndrome drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Carcinoid Syndrome

There are approx. 10+ key companies which are developing the therapies for Carcinoid Syndrome. The companies which have their Carcinoid Syndrome drug candidates in the most advanced stage, i.e. Phase I include, Crinetics Pharmaceuticals.

Phases

This report covers around 10+ products under different phases of clinical development like
  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration
Carcinoid Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
  • Oral
  • Parenteral
  • Intravitreal
  • Subretinal
  • Topical
  • Molecule Type
Products have been categorized under various Molecule types such as
  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Carcinoid Syndrome: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Carcinoid Syndrome therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Carcinoid Syndrome drugs.

Carcinoid Syndrome Report Insights
  • Carcinoid Syndrome Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs
Carcinoid Syndrome Report Assessment
  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs
Key Questions Answered

Current Treatment Scenario and Emerging Therapies:
  • How many companies are developing Carcinoid Syndrome drugs?
  • How many Carcinoid Syndrome drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Carcinoid Syndrome?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Carcinoid Syndrome therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Carcinoid Syndrome and their status?
  • What are the key designations that have been granted to the emerging drugs?


This report will be delivered within 2 business days.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Aquestive Therapeutics
  • Crinetics Pharmaceuticals
  • MORE
Introduction

Executive Summary

Carcinoid Syndrome: Overview
  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management
Pipeline Therapeutics
  • Comparative Analysis
Therapeutic Assessment
  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type
Carcinoid Syndrome - Analytical Perspective

In-depth Commercial Assessment
  • Carcinoid Syndrome companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Carcinoid Syndrome Collaboration Deals
  • Company-Company Collaborations (Licensing/Partnering) Analysis
  • Company-University Collaborations (Licensing/Partnering) Analysis
Early Stage Products (Phase I)
  • Comparative Analysis
Paltusotine: Crinetics Pharmaceuticals
  • Product Description
  • Research and Development
  • Product Development Activities
Preclinical Stage Products
  • Comparative Analysis
AQST-305: Aquestive Therapeutics
  • Product Description
  • Research and Development
  • Product Development Activities
Inactive Products
  • Comparative Analysis
Carcinoid Syndrome Key Companies

Carcinoid Syndrome Key Products

Carcinoid Syndrome- Unmet Needs

Carcinoid Syndrome- Market Drivers and Barriers

Carcinoid Syndrome- Future Perspectives and Conclusion

Carcinoid Syndrome Analyst Views

Carcinoid Syndrome Key Companies

Appendix

List of Tables
Table 1 Total Products for Carcinoid Syndrome
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

List of Figures
Figure 1 Total Products for Carcinoid Syndrome
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Note: Product cover images may vary from those shown
  • Aquestive Therapeutics
  • Crinetics Pharmaceuticals
Note: Product cover images may vary from those shown
Adroll
adroll